孕酮

常用名 孕酮 英文名 Progesterone
CAS号 57-83-0 分子量 314.462
密度 1.1±0.1 g/cm3 沸点 447.2±45.0 °C at 760 mmHg
分子式 C21H30O2 熔点 128-132 °C(lit.)
MSDS孕酮的MSDS|SDS|pdf下载 中文版 美版 闪点 166.7±25.7 °C
符号 GHS08
GHS08
信号词 Warning

 孕酮用途


激素类药。主要促进并维持妊娠前期的子宫变化,用于习惯性流产,月经不调等。


 孕酮名称

[ 中文名 ]: 孕酮
[ 英文名 ]: progesterone
[中文别名 ]: 黄体酮
助孕素
孕烯二酮
[英文别名 ]: Prontogest
(8S,9S,10R,13S,14S,17S)-17-Acetyl-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one
PREGN-4-EN-3,20-DIONE
lutren
(8S,9S,10R,13S,14S,17S)-17-Acetyl-10,13-dimethyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-3H-cyclopenta[a]phenanthren-3-one
EINECS 200-350-6
Vitarrine
4-Pregnen-3,20-dione
(8S,9S,10R,13S,14S,17S)-17-acétyl-10,13-diméthyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tétradécahydro-3H-cyclopenta[a]phénanthrén-3-one
U 3672
Progestogel
(8S,9S,10R,13S,14S,17S)-17-Acetyl-10,13-dimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3(2H)-one
progestérone
(8S,9S,10R,13S,14S,17S)-17-Acetyl-10,13-dimethyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-3H-cyclopenta[a]phenanthren-3-on
Luteol
Luteum
Lugesteron
MFCD00003658
Lutein
CIDR
Gestron
Progestol
Pregn-4-ene-3,20-dione
D4-Pregnene-3,20-dione
Lutin
Crinone
4-Pregnene-3,20-dione
Progesterone
Lutex
Gestiron

 孕酮物理化学性质

[ 密度 ]: 1.1±0.1 g/cm3
[ 沸点 ]: 447.2±45.0 °C at 760 mmHg
[ 熔点 ]: 128-132 °C(lit.)
[ 分子式 ]: C21H30O2
[ 分子量 ]: 314.462
[ 闪点 ]: 166.7±25.7 °C
[ 精确质量 ]: 314.224579
[ PSA ]: 34.14000
[ LogP ]: 4.04
[ 外观性状 ]: 结晶粉末
[ 蒸汽压 ]: 0.0±1.1 mmHg at 25°C
[ 折射率 ]: 1.542
[ 储存条件 ]:

本品应密封于阴凉干燥处避光保存。

[ 分子结构 ]:

五、分子性质数据:

1、 摩尔折射率:90.95

2、 摩尔体积(m3/mol):288.9

3、 等张比容(90.2K):731.9

4、 表面张力(dyne/cm):41.1

5、 极化率(10 -24cm 3):36.05

[ 计算化学 ]:

1.疏水参数计算参考值(XlogP):无

2.氢键供体数量:0

3.氢键受体数量:2

4.可旋转化学键数量:1

5.互变异构体数量:15

6.拓扑分子极性表面积34.1

7.重原子数量:23

8.表面电荷:0

9.复杂度:589

10.同位素原子数量:0

11.确定原子立构中心数量:6

12.不确定原子立构中心数量:0

13.确定化学键立构中心数量:0

14.不确定化学键立构中心数量:0

15.共价键单元数量:1

[ 更多 ]:

1. 性状:白色结晶或粉末。有两种于互变的结晶体,α型为柱状,β型为针状,具有相同生理活性。

2. 密度(g/mL,25/4℃):未确定

3. 相对蒸汽密度(g/mL,空气=1):未确定

4. 熔点(ºC):(α型)127-131℃,(β型)121℃

5. 沸点(ºC,常压): 未确定

6. 沸点(ºC,5.2kPa):未确定

7. 折射率:未确定

8. 闪点(ºC):未确定

9. 比旋光度(º):未确定

10. 自燃点或引燃温度(ºC):未确定

11. 蒸气压(kPa,25ºC):未确定

12. 饱和蒸气压(kPa,60ºC):未确定

13. 燃烧热(KJ/mol):未确定

14. 临界温度(ºC):未确定

15. 临界压力(KPa):未确定

16. 油水(辛醇/水)分配系数的对数值:未确定

17. 爆炸上限(%,V/V):未确定

18. 爆炸下限(%,V/V):未确定

19. 溶解性:溶于醇、丙酮和二氧六环微溶于植物油,不溶于水。在空气中稳定。

 孕酮MSDS


模块1. 化学品
1.1 产品标识符
: 孕酮
产品名称
: Vetec
1.2 鉴别的其他方法
无数据资料
1.3 有关的确定了的物质或混合物的用途和建议不适合的用途
仅供科研用途,不作为药物、家庭备用药或其它用途。

模块2. 危险性概述
2.1 GHS分类
急性毒性, 经口 (类别5)
致畸性 (类别2)
2.2 GHS 标记要素,包括预防性的陈述
象形图
警示词警告
危险申明
H303吞咽可能有害。
H361怀疑对生育能力或胎儿造成伤害。
警告申明
预防
P201在使用前获取特别指示。
P202在读懂所有安全防范措施之前切勿操作。
P281使用所需的个人防护设备。
措施
P308 + P313如接触到或有疑虑:求医/ 就诊。
储存
P405存放处须加锁。
处理
P501将内容物/ 容器处理到得到批准的废物处理厂。
2.3 其它危害物 - 无

模块3. 成分/组成信息
3.1 物 质
: C21H30O2
分子式
: 314.47 g/mol
分子量
组分浓度或浓度范围
Progesterone
-
CAS 号57-83-0
EC-编号200-350-6

模块4. 急救措施
4.1 必要的急救措施描述
一般的建议
请教医生。 出示此安全技术说明书给到现场的医生看。
吸入
如果吸入,请将患者移到新鲜空气处。 如果停止了呼吸,给于人工呼吸。 请教医生。
皮肤接触
用肥皂和大量的水冲洗。 请教医生。
眼睛接触
用水冲洗眼睛作为预防措施。
食入
切勿给失去知觉者从嘴里喂食任何东西。 用水漱口。 请教医生。
4.2 主要症状和影响,急性和迟发效应
据我们所知,此化学,物理和毒性性质尚未经完整的研究。
4.3 及时的医疗处理和所需的特殊处理的说明和指示
无数据资料

模块5. 消防措施
5.1 灭火介质
灭火方法及灭火剂
用水雾,耐醇泡沫,干粉或二氧化碳灭火。
5.2 源于此物质或混合物的特别的危害
碳氧化物
5.3 给消防员的建议
如必要的话,戴自给式呼吸器去救火。
5.4 进一步信息
无数据资料

模块6. 泄露应急处理
6.1 人员的预防,防护设备和紧急处理程序
使用个人防护设备。 防止粉尘的生成。 防止吸入蒸汽、气雾或气体。 保证充分的通风。
将人员撤离到安全区域。 避免吸入粉尘。
6.2 环境保护措施
在确保安全的前提下,采取措施防止进一步的泄漏或溢出。 不要让产物进入下水道。
6.3 抑制和清除溢出物的方法和材料
收集、处理泄漏物,不要产生灰尘。 扫掉和铲掉。 存放进适当的闭口容器中待处理。
6.4 参考其他部分
丢弃处理请参阅第13节。

模块7. 操作处置与储存
7.1 安全操作的注意事项
避免接触皮肤和眼睛。 防止粉尘和气溶胶生成。
在有粉尘生成的地方,提供合适的排风设备。
7.2 安全储存的条件,包括任何不兼容性
贮存在阴凉处。 容器保持紧闭,储存在干燥通风处。
对光线敏感
7.3 特定用途
无数据资料

模块8. 接触控制和个体防护
8.1 容许浓度
最高容许浓度
没有已知的国家规定的暴露极限。
8.2 暴露控制
适当的技术控制
按照良好工业和安全规范操作。 休息前和工作结束时洗手。
个体防护设备
眼/面保护
带有防护边罩的安全眼镜符合 EN166要求请使用经官方标准如NIOSH (美国) 或 EN 166(欧盟)
检测与批准的设备防护眼部。
皮肤保护
戴手套取 手套在使用前必须受检查。
请使用合适的方法脱除手套(不要接触手套外部表面),避免任何皮肤部位接触此产品.
使用后请将被污染过的手套根据相关法律法规和有效的实验室规章程序谨慎处理. 请清洗并吹干双手
所选择的保护手套必须符合EU的89/686/EEC规定和从它衍生出来的EN 376标准。
身体保护
防渗透的衣服, 防护设备的类型必须根据特定工作场所中的危险物的浓度和含量来选择。
呼吸系统防护
如危险性评测显示需要使用空气净化的防毒面具,请使用全面罩式多功能微粒防毒面具N100型(US
)或P3型(EN
143)防毒面具筒作为工程控制的候补。如果防毒面具是保护的唯一方式,则使用全面罩式送风防毒
面具。 呼吸器使用经过测试并通过政府标准如NIOSH(US)或CEN(EU)的呼吸器和零件。

模块9. 理化特性
9.1 基本的理化特性的信息
a) 外观与性状
形状: 固体
b) 气味
无数据资料
c) 气味阈值
无数据资料
d) pH值
无数据资料
e) 熔点/凝固点
128 °C
f) 起始沸点和沸程
无数据资料
g) 闪点
无数据资料
h) 蒸发速率
无数据资料
i) 易燃性(固体,气体)
无数据资料
j) 高的/低的燃烧性或爆炸性限度 无数据资料
k) 蒸汽压
无数据资料
l) 蒸汽密度
无数据资料
m) 相对密度
无数据资料
n) 水溶性
不溶
o) n-辛醇/水分配系数
无数据资料
p) 自燃温度
无数据资料
q) 分解温度
无数据资料
r) 粘度
无数据资料

模块10. 稳定性和反应活性
10.1 反应性
无数据资料
10.2 稳定性
无数据资料
10.3 危险反应的可能性
无数据资料
10.4 应避免的条件
无数据资料
10.5 不兼容的材料
强氧化剂
10.6 危险的分解产物

模块11. 毒理学资料
11.1 毒理学影响的信息
急性毒性
半数致死剂量 (LD50) 经口 - 大鼠 - 5,000 mg/kg
皮肤刺激或腐蚀
无数据资料
眼睛刺激或腐蚀
无数据资料
呼吸道或皮肤过敏
导致光敏。光照会引起过敏反应导致皮肤损伤,表现为晒斑、水肿、水泡或疹子等不同形式。
生殖细胞突变性
细胞突变性-体外试验 - 大鼠 - 胚胎
形态变形
细胞突变性-体内试验 - 大鼠 - 经口
微核测试
致癌性
该产品是或包含被IARC, ACGIH, EPA, 和 NTP 列为致癌物的组分
在对动物的研究中,只有有限的致癌迹象
IARC:
此产品中没有大于或等于 0。1%含量的组分被 IARC鉴别为可能的或肯定的人类致癌物。
生殖毒性
疑似人类生殖毒性
从实验动物的结果看,过度接触能导致生殖紊乱
特异性靶器官系统毒性(一次接触)
无数据资料
特异性靶器官系统毒性(反复接触)
无数据资料
吸入危险
无数据资料
潜在的健康影响
吸入吸入可能有害。 可能引起呼吸道刺激。
摄入如服入是有害的。
皮肤如果通过皮肤吸收可能是有害的。 可能引起皮肤刺激。
眼睛可能引起眼睛刺激。
接触后的征兆和症状
据我们所知,此化学,物理和毒性性质尚未经完整的研究。
附加说明
化学物质毒性作用登记: 无数据资料

模块12. 生态学资料
12.1 生态毒性
无数据资料
12.2 持久存留性和降解性
无数据资料
12.3 潜在的生物蓄积性
无数据资料
12.4 土壤中的迁移性
无数据资料
12.5 PBT 和 vPvB的结果评价
无数据资料
12.6 其它不利的影响
无数据资料

模块13. 废弃处置
13.1 废物处理方法
产品
将剩余的和未回收的溶液交给处理公司。
与易燃溶剂相溶或者相混合,在备有燃烧后处理和洗刷作用的化学焚化炉中燃烧
受污染的容器和包装
作为未用过的产品弃置。

模块14. 运输信息
14.1 联合国危险货物编号
欧洲陆运危规: -国际海运危规: -国际空运危规: -
14.2 联合国(UN)规定的名称
欧洲陆运危规: 非危险货物
国际海运危规: 非危险货物
国际空运危规: 非危险货物
14.3 运输危险类别
欧洲陆运危规: -国际海运危规: -国际空运危规: -
14.4 包裹组
欧洲陆运危规: -国际海运危规: -国际空运危规: -
14.5 环境危险
欧洲陆运危规: 否国际海运危规 海运污染物: 否国际空运危规: 否
14.6 对使用者的特别提醒
无数据资料


模块 15 - 法规信息
N/A


模块16 - 其他信息
N/A

 孕酮毒性和生态

CHEMICAL IDENTIFICATION

RTECS NUMBER :
TW0175000
CHEMICAL NAME :
Progesterone
CAS REGISTRY NUMBER :
57-83-0
LAST UPDATED :
199806
DATA ITEMS CITED :
132
MOLECULAR FORMULA :
C21-H30-O2
MOLECULAR WEIGHT :
314.51
WISWESSER LINE NOTATION :
L E5 B666 OV MUTJ A1 E1 FV1

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
327 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
100 mg/kg
TOXIC EFFECTS :
Behavioral - convulsions or effect on seizure threshold Behavioral - ataxia Lungs, Thorax, or Respiration - dyspnea
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
40 mg/kg
TOXIC EFFECTS :
Tumorigenic - neoplastic by RTECS criteria Skin and Appendages - tumors
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Parenteral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
1289 mg/kg/78W-C
TOXIC EFFECTS :
Tumorigenic - equivocal tumorigenic agent by RTECS criteria Reproductive - Tumorigenic effects - ovarian tumors Reproductive - Tumorigenic effects - uterine tumors
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Implant
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
1296 mg/kg/77W-C
TOXIC EFFECTS :
Tumorigenic - neoplastic by RTECS criteria Tumorigenic - increased incidence of tumors in susceptible strains
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
26643 mg/kg/4Y-I
TOXIC EFFECTS :
Tumorigenic - equivocal tumorigenic agent by RTECS criteria Skin and Appendages - tumors
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Implant
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
270 mg/kg/78W
TOXIC EFFECTS :
Tumorigenic - equivocal tumorigenic agent by RTECS criteria Liver - tumors
TYPE OF TEST :
TD - Toxic dose (other than lowest)
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
9500 mg/kg/19W-I
TOXIC EFFECTS :
Tumorigenic - neoplastic by RTECS criteria Skin and Appendages - tumors
TYPE OF TEST :
TD - Toxic dose (other than lowest)
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
200 mg/kg/5W-I
TOXIC EFFECTS :
Tumorigenic - equivocal tumorigenic agent by RTECS criteria Blood - leukemia
TYPE OF TEST :
TD - Toxic dose (other than lowest)
ROUTE OF EXPOSURE :
Implant
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
1300 mg/kg/78W-I
TOXIC EFFECTS :
Tumorigenic - neoplastic by RTECS criteria Reproductive - Tumorigenic effects - ovarian tumors
TYPE OF TEST :
TD - Toxic dose (other than lowest)
ROUTE OF EXPOSURE :
Implant
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
2592 mg/kg/77W-C
TOXIC EFFECTS :
Tumorigenic - neoplastic by RTECS criteria Tumorigenic - increased incidence of tumors in susceptible strains
TYPE OF TEST :
TD - Toxic dose (other than lowest)
ROUTE OF EXPOSURE :
Implant
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
14 gm/kg/77W-C
TOXIC EFFECTS :
Tumorigenic - neoplastic by RTECS criteria Tumorigenic - increased incidence of tumors in susceptible strains
TYPE OF TEST :
TD - Toxic dose (other than lowest)
ROUTE OF EXPOSURE :
Implant
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
648 mg/kg/77W-C
TOXIC EFFECTS :
Tumorigenic - equivocal tumorigenic agent by RTECS criteria Tumorigenic - increased incidence of tumors in susceptible strains
TYPE OF TEST :
TD - Toxic dose (other than lowest)
ROUTE OF EXPOSURE :
Implant
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
216 mg/kg/77W-C
TOXIC EFFECTS :
Tumorigenic - equivocal tumorigenic agent by RTECS criteria Tumorigenic - increased incidence of tumors in susceptible strains
TYPE OF TEST :
TD - Toxic dose (other than lowest)
ROUTE OF EXPOSURE :
Implant
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
19 gm/kg/77W-C
TOXIC EFFECTS :
Tumorigenic - equivocal tumorigenic agent by RTECS criteria Tumorigenic - increased incidence of tumors in susceptible strains
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
200 mg/kg
SEX/DURATION :
female 20 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Maternal Effects - uterus, cervix, vagina
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
113 mg/kg
SEX/DURATION :
female 6-32 week(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - urogenital system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
120 mg/kg
SEX/DURATION :
female 20 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Fertility - other measures of fertility
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
100 mg/kg
SEX/DURATION :
female 20 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Maternal Effects - uterus, cervix, vagina
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
120 mg/kg
SEX/DURATION :
female 20 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Maternal Effects - menstrual cycle changes or disorders Reproductive - Fertility - female fertility index (e.g. # females pregnant per # sperm positive females; # females pregnant per # females mated) Reproductive - Fertility - other measures of fertility
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
DOSE :
50 mg/kg
SEX/DURATION :
male 70 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Paternal Effects - spermatogenesis (incl. genetic material, sperm morphology, motility, and count) Reproductive - Paternal Effects - breast development
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
DOSE :
15 mg/kg
SEX/DURATION :
male 21 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Paternal Effects - impotence
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Parenteral
DOSE :
600 ug/kg
SEX/DURATION :
female 67-71 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - urogenital system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Parenteral
DOSE :
32 mg/kg
SEX/DURATION :
female 3 week(s) pre-mating
TOXIC EFFECTS :
Reproductive - Maternal Effects - menstrual cycle changes or disorders
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Unreported
DOSE :
386 mg/kg
SEX/DURATION :
female 18-34 week(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - urogenital system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravaginal
DOSE :
210 mg/kg
SEX/DURATION :
female 3 week(s) pre-mating
TOXIC EFFECTS :
Reproductive - Maternal Effects - menstrual cycle changes or disorders
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravaginal
DOSE :
475 ug/kg
SEX/DURATION :
female 1 year(s) pre-mating
TOXIC EFFECTS :
Reproductive - Maternal Effects - menstrual cycle changes or disorders
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
25 mg/kg
SEX/DURATION :
female 1 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Fertility - mating performance (e.g. # sperm positive females per # females mated; # copulations per # estrus cycles)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
180 mg/kg
SEX/DURATION :
male 9 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Paternal Effects - prostate, seminal vesicle, Cowper's gland, accessory glands
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
50 mg/kg
SEX/DURATION :
female 1 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Fertility - mating performance (e.g. # sperm positive females per # females mated; # copulations per # estrus cycles)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
700 mg/kg
SEX/DURATION :
female 14 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Maternal Effects - uterus, cervix, vagina
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Administration onto the skin
DOSE :
240 mg/kg
SEX/DURATION :
male 30 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Paternal Effects - prostate, seminal vesicle, Cowper's gland, accessory glands Reproductive - Paternal Effects - prostate, seminal vesicle, Cowper's gland, accessory glands
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
7 mg/kg
SEX/DURATION :
female 10-16 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - abortion
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
188 mg/kg
SEX/DURATION :
female 30 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Maternal Effects - menstrual cycle changes or disorders
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
420 mg/kg
SEX/DURATION :
female 15-17 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetal death
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
9 mg/kg
SEX/DURATION :
female 15-20 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - urogenital system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
4 mg/kg
SEX/DURATION :
female 9 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - Central Nervous System
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
1 mg/kg
SEX/DURATION :
female 9 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - behavioral
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
500 ug/kg
SEX/DURATION :
female 2 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Fertility - other measures of fertility
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
20 mg/kg
SEX/DURATION :
female 23 day(s) after conception
TOXIC EFFECTS :
Reproductive - Maternal Effects - parturition Reproductive - Maternal Effects - postpartum Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
DOSE :
110 mg/kg
SEX/DURATION :
female 1-22 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - delayed effects
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
DOSE :
900 ug/kg
SEX/DURATION :
female 6-14 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
DOSE :
200 mg/kg
SEX/DURATION :
male 48 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Paternal Effects - testes, epididymis, sperm duct Reproductive - Paternal Effects - prostate, seminal vesicle, Cowper's gland, accessory glands Reproductive - Paternal Effects - other effects on male
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
DOSE :
30 mg/kg
SEX/DURATION :
female 1-6 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
DOSE :
35 mg/kg
SEX/DURATION :
female 14-20 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - extra-embryonic structures (e.g., placenta, umbilical cord)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intracerebral
DOSE :
250 ug/kg
SEX/DURATION :
female 1 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Fertility - other measures of fertility
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Parenteral
DOSE :
36300 ug/kg
SEX/DURATION :
female 7-17 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Effects on Newborn - biochemical and metabolic
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Parenteral
DOSE :
8750 ug/kg
SEX/DURATION :
female 7 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Maternal Effects - uterus, cervix, vagina
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Parenteral
DOSE :
60 ug/kg
SEX/DURATION :
female 16-19 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - blood and lymphatic systems (including spleen and marrow)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Implant
DOSE :
250 ug/kg
SEX/DURATION :
lactating female 2 day(s) post-birth
TOXIC EFFECTS :
Reproductive - Maternal Effects - postpartum
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Implant
DOSE :
30 mg/kg
SEX/DURATION :
female 24 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Maternal Effects - ovaries, fallopian tubes
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Unreported
DOSE :
100 mg/kg
SEX/DURATION :
female 20-24 day(s) after conception
TOXIC EFFECTS :
Reproductive - Maternal Effects - parturition
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
240 mg/kg
SEX/DURATION :
female 14-16 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - biochemical and metabolic Reproductive - Effects on Newborn - delayed effects
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
100 mg/kg
SEX/DURATION :
female 1 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - other measures of fertility
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
20 mg/kg
SEX/DURATION :
female 6-9 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
1500 ug/kg
SEX/DURATION :
female 3 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Maternal Effects - uterus, cervix, vagina
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
2400 mg/kg
SEX/DURATION :
male 20 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Paternal Effects - testes, epididymis, sperm duct
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Implant
DOSE :
3 gm/kg
SEX/DURATION :
female 5 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Maternal Effects - uterus, cervix, vagina
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Unreported
DOSE :
10 mg/kg
SEX/DURATION :
female 1 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Fertility - other measures of fertility
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
16 mg/kg
SEX/DURATION :
female 5 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Maternal Effects - uterus, cervix, vagina
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Implant
DOSE :
360 mg/kg
SEX/DURATION :
female 34 week(s) pre-mating
TOXIC EFFECTS :
Reproductive - Fertility - other measures of fertility
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Implant
DOSE :
600 mg/kg
SEX/DURATION :
female 60 week(s) pre-mating
TOXIC EFFECTS :
Reproductive - Maternal Effects - breasts, lactation (prior to or during pregnancy)
TYPE OF TEST :
TCLo - Lowest published toxic concentration
ROUTE OF EXPOSURE :
Inhalation
DOSE :
30 ug/kg/30M
SEX/DURATION :
male 60 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Paternal Effects - spermatogenesis (incl. genetic material, sperm morphology, motility, and count) Reproductive - Paternal Effects - testes, epididymis, sperm duct
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Inhalation
DOSE :
4 ug/kg
SEX/DURATION :
female 10 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Fertility - other measures of fertility
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
900 ug/kg
SEX/DURATION :
female 9 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Fertility - other measures of fertility
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
DOSE :
12 mg/kg
SEX/DURATION :
female 8 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Fertility - other measures of fertility
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravaginal
DOSE :
85410 ug/kg
SEX/DURATION :
female 52 week(s) pre-mating
TOXIC EFFECTS :
Reproductive - Maternal Effects - uterus, cervix, vagina Reproductive - Fertility - other measures of fertility
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravaginal
DOSE :
17155 ug/kg
SEX/DURATION :
female 52 week(s) pre-mating
TOXIC EFFECTS :
Reproductive - Maternal Effects - ovaries, fallopian tubes
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
1 mg/kg
SEX/DURATION :
female 1 day(s) pre-mating female 1 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - other measures of fertility
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
100 mg/kg
SEX/DURATION :
female 1 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Fertility - mating performance (e.g. # sperm positive females per # females mated; # copulations per # estrus cycles) Reproductive - Fertility - other measures of fertility
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Administration onto the skin
DOSE :
500 ug/kg
SEX/DURATION :
female 1 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Fertility - pre-implantation mortality (e.g. reduction in number of implants per female; total number of implants per corpora lutea)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Administration onto the skin
DOSE :
1 mg/kg
SEX/DURATION :
female 1 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Fertility - other measures of fertility
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
50 ug/kg
SEX/DURATION :
female 5 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Maternal Effects - uterus, cervix, vagina
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
50 ug/kg
SEX/DURATION :
female 1 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Fertility - other measures of fertility
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
70 mg/kg
SEX/DURATION :
male 14 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Paternal Effects - spermatogenesis (incl. genetic material, sperm morphology, motility, and count) Reproductive - Paternal Effects - other effects on male
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
300 ug/kg
SEX/DURATION :
female 2 day(s) pre-mating female 1 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - pre-implantation mortality (e.g. reduction in number of implants per female; total number of implants per corpora lutea)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
100 ug/kg
SEX/DURATION :
female 1 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Maternal Effects - ovaries, fallopian tubes
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
150 ug/kg
SEX/DURATION :
female 1 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Fertility - mating performance (e.g. # sperm positive females per # females mated; # copulations per # estrus cycles)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
DOSE :
8 mg/kg
SEX/DURATION :
female 2-9 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - pre-implantation mortality (e.g. reduction in number of implants per female; total number of implants per corpora lutea)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
DOSE :
8 mg/kg
SEX/DURATION :
female 25-32 day(s) after conception
TOXIC EFFECTS :
Reproductive - Maternal Effects - postpartum
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
DOSE :
2500 mg/kg
SEX/DURATION :
female 2 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Fertility - female fertility index (e.g. # females pregnant per # sperm positive females; # females pregnant per # females mated) Reproductive - Fertility - pre-implantation mortality (e.g. reduction in number of implants per female; total number of implants per corpora lutea) Reproductive - Specific Developmental Abnormalities - other developmental abnormalities
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Unreported
DOSE :
120 ug/kg
SEX/DURATION :
female 6-29 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - weaning or lactation index (e.g., # alive at weaning per # alive at day 4)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intrauterine
DOSE :
684 ug/kg
SEX/DURATION :
female 14 day(s) pre-mating female 1-10 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - pre-implantation mortality (e.g. reduction in number of implants per female; total number of implants per corpora lutea)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intrauterine
DOSE :
105 ug/kg
SEX/DURATION :
female 21 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Fertility - female fertility index (e.g. # females pregnant per # sperm positive females; # females pregnant per # females mated)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intrauterine
DOSE :
260 ug/kg
SEX/DURATION :
female 21 day(s) pre-mating female 1-31 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
2250 ug/kg
SEX/DURATION :
female 1-5 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - other measures of fertility
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
40 mg/kg
SEX/DURATION :
female 16 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Maternal Effects - ovaries, fallopian tubes
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
1667 ug/kg
SEX/DURATION :
female 1 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Fertility - other measures of fertility
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
DOSE :
18333 ug/kg
SEX/DURATION :
female 15-25 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - urogenital system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Parenteral
DOSE :
5833 ug/kg
SEX/DURATION :
female 14 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Maternal Effects - menstrual cycle changes or disorders
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
86 mg/kg
SEX/DURATION :
female 18-60 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - urogenital system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
DOSE :
1480 mg/kg
SEX/DURATION :
male 70 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Paternal Effects - testes, epididymis, sperm duct Reproductive - Fertility - mating performance (e.g. # sperm positive females per # females mated; # copulations per # estrus cycles)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
240 ug/kg
SEX/DURATION :
female 1 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Fertility - other measures of fertility
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
2 mg/kg
SEX/DURATION :
female 1 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Maternal Effects - uterus, cervix, vagina
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
80 mg/kg
SEX/DURATION :
female 1 day(s) after conception
TOXIC EFFECTS :
Reproductive - Maternal Effects - parturition Reproductive - Effects on Newborn - live birth index (measured after birth)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
32 mg/kg
SEX/DURATION :
female 1 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Fertility - female fertility index (e.g. # females pregnant per # sperm positive females; # females pregnant per # females mated)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Parenteral
DOSE :
2400 ug/kg
SEX/DURATION :
female 3 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Fertility - mating performance (e.g. # sperm positive females per # females mated; # copulations per # estrus cycles)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
3 mg/kg
SEX/DURATION :
male 30 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Paternal Effects - spermatogenesis (incl. genetic material, sperm morphology, motility, and count) Reproductive - Paternal Effects - other effects on male
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
1273 ug/kg
SEX/DURATION :
female 14 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Maternal Effects - menstrual cycle changes or disorders Reproductive - Fertility - other measures of fertility
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
DOSE :
2545 ug/kg
SEX/DURATION :
female 7 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Maternal Effects - menstrual cycle changes or disorders Reproductive - Fertility - female fertility index (e.g. # females pregnant per # sperm positive females; # females pregnant per # females mated)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
DOSE :
1700 ug/kg
SEX/DURATION :
female 39-41 week(s) after conception
TOXIC EFFECTS :
Reproductive - Maternal Effects - parturition
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Parenteral
DOSE :
16667 ug/kg
SEX/DURATION :
female 45-47 week(s) after conception
TOXIC EFFECTS :
Reproductive - Maternal Effects - parturition
TYPE OF TEST :
DNA damage
TYPE OF TEST :
Unscheduled DNA synthesis
TYPE OF TEST :
DNA inhibition
TYPE OF TEST :
DNA damage

MUTATION DATA

TEST SYSTEM :
Mammal - dog
DOSE/DURATION :
100 ug/kg
REFERENCE :
NATUAS Nature. (Nature Subscription Dept., POB 1018, Manasguan, NJ 08736) V.1- 1869- Volume(issue)/page/year: 220,1145,1968 *** REVIEWS *** IARC Cancer Review:Animal Sufficient Evidence IMSUDL IARC Monographs, Supplement. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) No.1- 1979- Volume(issue)/page/year: 7,296,1987 TOXICOLOGY REVIEW ACEDAB Acta Endocrinologica, Supplementum (Copenhagen). (Periodica, Skolegade 12 E, DK-2500 Valby, Denmark) No.1- 1948- Volume(issue)/page/year: 185,169,1974 TOXICOLOGY REVIEW PCNAA8 Pediatric Clinics of North America. (W.B. Saunders Co., W. Washington Sq., Philadelphia, PA 19105) V.1- 1954- Volume(issue)/page/year: 8,413,1961 TOXICOLOGY REVIEW JOPDAB Journal of Pediatrics. (C.V. Mosby Co., 11830 Westline Industrial Dr., St. Louis, MO 63141) V.1- 1932- Volume(issue)/page/year: 59,1,1961 TOXICOLOGY REVIEW CMROCX Current Medical Research and Opinion. (Clayton-Wray Pub. Ltd., 1a High St., Alton, Hants., UK) V.1- 1972- Volume(issue)/page/year: 4,309,1976 TOXICOLOGY REVIEW ACEDAB Acta Endocrinologica, Supplementum (Copenhagen). (Periodica, Skolegade 12 E, DK-2500 Valby, Denmark) No.1- 1948- Volume(issue)/page/year: 51,671,1960 TOXICOLOGY REVIEW JRPMAP Journal of Reproductive Medicine. (2 Jacklynn Ct., St. Louis, MO 63132) V.3- 1969- Volume(issue)/page/year: 13,113,1974 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOHS - National Occupational Hazard Survey (1974) NOHS Hazard Code - 84510 No. of Facilities: 134 (estimated) No. of Industries: 2 No. of Occupations: 9 No. of Employees: 22963 (estimated) NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - 84510 No. of Facilities: 55 (estimated) No. of Industries: 2 No. of Occupations: 2 No. of Employees: 287 (estimated) No. of Female Employees: 55 (estimated)

 孕酮安全信息

[ 符号 ]: GHS08
GHS08
[ 信号词 ]: Warning
[ 危害声明 ]: H351-H361
[ 警示性声明 ]: P280
[ 个人防护装备 ]: Eyeshields;full-face particle respirator type N100 (US);Gloves;respirator cartridge type N100 (US);type P1 (EN143) respirator filter;type P3 (EN 143) respirator cartridges
[ 危害码 (欧洲) ]: Xn:Harmful
[ 风险声明 (欧洲) ]: R40
[ 安全声明 (欧洲) ]: S36/37-S45
[ 危险品运输编码 ]: NONH for all modes of transport
[ WGK德国 ]: 3
[ RTECS号 ]: TW0175000

 孕酮合成线路

~99%

文献:Magnus; Waring; Scott Tetrahedron Letters, 2000 , vol. 41, # 50 p. 9731 - 9733

~95%

文献:Nagaoka, Masao; Kunitama, Yurie; Numazawa, Mitsuteru Journal of Organic Chemistry, 1991 , vol. 56, # 1 p. 334 - 338

~4%

文献:Journal of Organic Chemistry, , vol. 58, # 5 p. 1259 - 1261

~80%

文献:Vijayashree, N.; Samuuelson, Ashoka G. Tetrahedron Letters, 1992 , vol. 33, # 4 p. 559 - 560

~95%

文献:Jarman, Michael; McCague, Raymond Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999), 1987 , p. 1129 - 1134

~95%

文献:Nagaoka, Masao; Kunitama, Yurie; Numazawa, Mitsuteru Journal of Organic Chemistry, 1991 , vol. 56, # 1 p. 334 - 338

~91%

文献:Marcantoni, Enrico; Nobili, Francesco; Bartoli, Giuseppe; Bosco, Marcella; Sambri, Letizia Journal of Organic Chemistry, 1997 , vol. 62, # 12 p. 4183 - 4184

~87%

文献:Almeida, Maria L. S.; Kocovsky, Pavel; Backvall, Jan-E. Journal of Organic Chemistry, 1996 , vol. 61, # 19 p. 6587 - 6590

~99%

文献:Kamata; Haga; Matsui; Nagata Synthesis, 1986 , vol. NO. 7, p. 588 - 591

~94%

文献:Acosta, C. Kirk; Rao, Pemmaraju N.; Kim, Hyun K. Steroids, 1993 , vol. 58, # 5 p. 205 - 208

~56%

文献:Nagaoka, Masao; Kunitama, Yurie; Numazawa, Mitsuteru Journal of Organic Chemistry, 1991 , vol. 56, # 1 p. 334 - 338

~93%

文献:Mikhal'chuk, A. L.; Pschenichnyi, V. N. Journal of Organic Chemistry USSR (English Translation), 1991 , vol. 27, # 8.1 p. 1479 - 1485 Zhurnal Organicheskoi Khimii, 1991 , vol. 27, # 8 p. 1686 - 1693

~83%

文献:Cabellero; Gros Synthetic Communications, 1995 , vol. 25, # 3 p. 395 - 404

~4%

文献:Chemical and pharmaceutical bulletin, , vol. 34, # 9 p. 3722 - 3726

~83%

文献:Caballero, Gerardo M.; Gros, Eduardo G. Zeitschrift fur Naturforschung - Section B Journal of Chemical Sciences, 1997 , vol. 52, # 9 p. 1147 - 1151

~8%

详细
文献:Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999), , p. 1797 - 1804

~19%

文献:Nagaoka, Masao; Kunitama, Yurie; Numazawa, Mitsuteru Journal of Organic Chemistry, 1991 , vol. 56, # 1 p. 334 - 338

~%

文献:Journal of Organic Chemistry, , vol. 56, # 1 p. 334 - 338

~%

文献:Journal of the American Chemical Society, , vol. 63, p. 774,776 Journal of the American Chemical Society, , vol. 69, p. 2167,2172

~%

文献:US2153700 , ; DE672896 , ; Fortschr. Teerfarbenfabr. Verw. Industriezweige, vol. 24, p. 500

~3%

文献:Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999), , p. 463 - 468

~%

文献:Journal of the American Chemical Society, , vol. 72, p. 1751

~%

文献:Journal of the American Chemical Society, , vol. 72, p. 2617

~%

文献:Journal of the American Chemical Society, , vol. 62, p. 79

~35%

文献:Boar, Robin B.; Patel, Arvind C. Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999), 1985 , p. 1201 - 1204

~36%

文献:Chemical and pharmaceutical bulletin, , vol. 34, # 9 p. 3722 - 3726

~%

文献:Zeitschrift fur Chemie, , vol. 26, # 10 p. 369 - 369

~%

文献:Zeitschrift fur Chemie, , vol. 26, # 10 p. 369 - 369

~%

文献:Zeitschrift fur Chemie, , vol. 26, # 10 p. 369 - 369

~%

文献:Zeitschrift fur Chemie, , vol. 26, # 10 p. 369 - 369

~%

文献:Journal of the American Chemical Society, , vol. 63, p. 774,776 Journal of the American Chemical Society, , vol. 69, p. 2167,2172

~%

文献:Journal of the American Chemical Society, , vol. 63, p. 774,776 Journal of the American Chemical Society, , vol. 69, p. 2167,2172

~%

文献:US4315925 A1, ;

~8%

详细
文献:Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999), , p. 1797 - 1804

~87%

文献:Journal of Organic Chemistry, , vol. 56, # 1 p. 334 - 338

~%

文献:Journal of Organic Chemistry, , vol. 57, # 8 p. 2249 - 2252

~%

文献:Journal of Organic Chemistry, , vol. 57, # 8 p. 2249 - 2252

~%

文献:Journal of Organic Chemistry, , vol. 57, # 8 p. 2249 - 2252

~%

文献:Journal of Organic Chemistry, , vol. 57, # 8 p. 2249 - 2252

~15%

文献:Torrini; Romeo Farmaco, Edizione Scientifica, 1980 , vol. 35, # 8 p. 681 - 683

~%

文献:Journal of Organic Chemistry, , vol. 57, # 8 p. 2249 - 2252

~0%

文献:Yoshida, Hirokazu; Nakai, Shiro; Nimbari, Fusako; Yoshimoto, Kiyoko; Nishimura, Tadashi Steroids, 1989 , vol. 53, # 6 p. 727 - 738

~%

文献:Journal of the Chemical Society - Series Chemical Communications, , vol. NO. 1, p. 31 - 32

~%

详细
文献:Steroids, , vol. 73, # 14 p. 1441 - 1445

~%

文献:Journal of the Chemical Society, , p. 2627,2630 Journal of the American Chemical Society, , vol. 77, p. 1212,1215 Journal of the Chemical Society, , p. 1302,1305

~%

文献:US2256500 , ; DE686759 , ; Fortschr. Teerfarbenfabr. Verw. Industriezweige, vol. 24, p. 502 Journal of the American Chemical Society, , vol. 63, p. 774,776 Journal of the American Chemical Society, , vol. 69, p. 2167,2172

~%

文献:Chemical and pharmaceutical bulletin, , vol. 34, # 9 p. 3722 - 3726

~%

文献:Synthesis, , vol. NO. 7, p. 588 - 591

~%

文献:Synthesis, , vol. NO. 7, p. 588 - 591

~%

文献:Synthesis, , vol. NO. 7, p. 588 - 591

~%

文献:Synthesis, , vol. NO. 7, p. 588 - 591

~%

文献:Synthesis, , # 7 p. 531 - 532

~%

文献:Synthesis, , # 7 p. 531 - 532

~%

文献:Helvetica Chimica Acta, , vol. 32, p. 1758,1761

~%

文献:Helvetica Chimica Acta, , vol. 32, p. 1517,1528

~%

文献:Synthetic Communications, , vol. 20, # 1 p. 131 - 136

~%

文献:Helvetica Chimica Acta, , vol. 63, # 8 p. 2328 - 2337

~%

文献:Helvetica Chimica Acta, , vol. 63, # 8 p. 2328 - 2337

~%

文献:Helvetica Chimica Acta, , vol. 23, p. 684,686

~8%

文献:Journal of Organic Chemistry USSR (English Translation), , vol. 25, # 3.2 p. 507 - 512 Zhurnal Organicheskoi Khimii, , vol. 25, # 3 p. 565 - 571

~%

文献:Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999), , p. 1201 - 1204

~%

文献:Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999), , p. 1201 - 1204

~%

文献:Journal of Organic Chemistry, , vol. 24, p. 1629,1632

~%

文献:Helvetica Chimica Acta, , vol. 29, p. 627,630 Helvetica Chimica Acta, , vol. 30, p. 1022,1025 Helvetica Chimica Acta, , vol. 30, p. 1405,1407

~%

文献:Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999), , p. 463 - 468

~%

文献:Journal of Labelled Compounds and Radiopharmaceuticals, , vol. 41, # 3 p. 221 - 226

~%

文献:Helvetica Chimica Acta, , vol. 29, p. 627,630

~%

文献:Chemische Berichte, , vol. 72, p. 1112,1116

~%

文献:Journal of the American Chemical Society, , vol. 62, p. 2537,2539 Journal of the American Chemical Society, , vol. 69, p. 2395 US2108646 , ; Journal of the American Chemical Society, , vol. 60, p. 1565,1566 Journal of the American Chemical Society, , vol. 61, p. 2537 GB488103 , ; CH198836 , ; Journal of Biological Chemistry, , vol. 157, p. 601,610 Journal of Biological Chemistry, , vol. 184, p. 259,271 Angewandte Chemie, , vol. 52, p. 363,366

~%

文献:US2310150 , ; DE739083 , ; DRP/DRBP Org.Chem. CH219649 , ;

~%

文献:Chemische Berichte, , vol. 67, p. 2027,2029 Journal of Biological Chemistry, , vol. 107, p. 321,332 Chemische Berichte, , vol. 67, p. 2092,2094

~%

文献:Chemische Berichte, , vol. 67, p. 2027,2029 Journal of Biological Chemistry, , vol. 107, p. 321,332 Chemische Berichte, , vol. 67, p. 2092,2094

~%

文献:Chemische Berichte, , vol. 67, p. 2027,2029 Journal of Biological Chemistry, , vol. 107, p. 321,332 Chemische Berichte, , vol. 67, p. 2092,2094

~%

文献:Chemische Berichte, , vol. 67, p. 2027,2029 Journal of Biological Chemistry, , vol. 107, p. 321,332 Chemische Berichte, , vol. 67, p. 2092,2094

~%

文献:Chemische Berichte, , vol. 67, p. 2027,2029 Journal of Biological Chemistry, , vol. 107, p. 321,332 Chemische Berichte, , vol. 67, p. 2092,2094

~%

文献:Chemische Berichte, , vol. 67, p. 2027,2029 Journal of Biological Chemistry, , vol. 107, p. 321,332 Chemische Berichte, , vol. 67, p. 2092,2094

~%

文献:US2752368 , ; DE932799 , ;

~%

文献:US2310150 , ; DE739083 , ; DRP/DRBP Org.Chem.

~%

文献:Helvetica Chimica Acta, , vol. 30, p. 1022,1025

~%

文献:Helvetica Chimica Acta, , vol. 29, p. 627,630

~%

文献:Helvetica Chimica Acta, , vol. 30, p. 1022,1025

~%

文献:Helvetica Chimica Acta, , vol. 30, p. 1022,1025

~%

文献:Helvetica Chimica Acta, , vol. 30, p. 1022,1025

~%

文献:Helvetica Chimica Acta, , vol. 29, p. 627,630

~%

文献:Helvetica Chimica Acta, , vol. 29, p. 627,630

~%

文献:US2697106 , ;

~%

文献:Chemische Berichte, , vol. 69, p. 889,892

~%

文献:Chemische Berichte, , vol. 72, p. 1112,1116

~%

文献:Journal of Biochemistry (Tokyo, Japan), , vol. 44, p. 51,54 Gazzetta Chimica Italiana, , vol. 83, p. 795,799 Canadian Journal of Chemistry, , vol. 34, p. 982,986 Proceedings of the Japan Academy, , vol. 32, p. 611,612

~%

文献:Chemische Berichte, , vol. 67, p. 2085,2087 Chemische Berichte, , vol. 69, p. 443,447

~%

文献:Chemische Berichte, , vol. 72, p. 1112,1116

~%

文献:Chemische Berichte, , vol. 72, p. 1112,1116

~%

文献:Chemische Berichte, , vol. 72, p. 1112,1116

~%

文献:Chemische Berichte, , vol. 72, p. 1112,1116

~%

文献:Journal of Biological Chemistry, , vol. 287, # 20 p. 16609 - 16622

~%

文献:US2333202 , ;

~%

文献:Helvetica Chimica Acta, , vol. 32, p. 1922,1930

~%

文献:CH213180 , ;

~%

文献:Journal of the American Chemical Society, , vol. 62, p. 3349

~6%

详细
文献:Steroids, , vol. 74, # 10-11 p. 859 - 862

~%

文献:DE833961 , ; DRP/DRBP Org.Chem. US2601287 , ;

~%

文献:US2256500 , ; DE686759 , ; Fortschr. Teerfarbenfabr. Verw. Industriezweige, vol. 24, p. 502 Journal of the American Chemical Society, , vol. 63, p. 774,776 Journal of the American Chemical Society, , vol. 69, p. 2167,2172

~%

文献:Steroids, , vol. 43, # 3 p. 315 - 323

~%

详细
文献:Steroids, , vol. 31, # 3 p. 315 - 325

~%

文献:Acta Chemica Scandinavica, Series B: Organic Chemistry and Biochemistry, , vol. 35, # 6 p. 407 - 410

~%

详细
文献:Steroids, , vol. 31, # 3 p. 315 - 325

~%

文献:Journal of the American Chemical Society, , vol. 62, p. 2537,2539

~%

详细
文献:Steroids, , vol. 42, # 6 p. 641 - 651

~%

文献:Doklady Chemistry, , vol. 279, p. 402 - 404 Dokl. Akad. Nauk SSSR Ser. Khim., , vol. 279, # 2 p. 396 - 398

~%

文献:Journal of Pharmaceutical Sciences, , vol. 71, # 5 p. 514 - 520

~%

文献:Journal of Pharmaceutical Sciences, , vol. 71, # 5 p. 514 - 520

~%

文献:Journal of Pharmaceutical Sciences, , vol. 71, # 5 p. 514 - 520

~%

文献:Journal of Pharmaceutical Sciences, , vol. 71, # 5 p. 514 - 520

~%

文献:Journal of Pharmaceutical Sciences, , vol. 71, # 5 p. 514 - 520

~%

详细
文献:Journal of the American Chemical Society, , vol. 69, p. 2395

~%

文献:Steroids, , vol. 39, # 3 p. 259 - 278

~%

详细
文献:Biochim. Terap. sperim., , vol. 28, p. 1,4 Journal of the American Chemical Society, , vol. 61, p. 893

~%

文献:Hoppe-Seyler's Zeitschrift fuer Physiologische Chemie, , vol. 252, p. 49,51 CH214603 , ; CH221804 , ;

~%

详细
文献:Helvetica Chimica Acta, , vol. 29, p. 627,630 Helvetica Chimica Acta, , vol. 30, p. 1022,1025 Helvetica Chimica Acta, , vol. 30, p. 1405,1407

~%

文献:Helvetica Chimica Acta, , vol. 32, p. 1758,1761

~%

文献:US2413000 , ;

~%

文献:US2413000 , ;

~%

详细
文献:DE733297 , ; DRP/DRBP Org.Chem. DE711823 , ; DRP/DRBP Org.Chem. CH225920 , ; CH221805 , ; CH221806 , ;

~%

文献:US2379832 , ;

~%

文献:US2397424 , ; US2397426 , ; US2323277 , ; CH235279 , ; US2397425 , ;

~%

文献:US2413000 , ;

~%

文献:Journal of Organic Chemistry, , vol. 28, p. 3557

~%

文献:Journal of Organic Chemistry, , vol. 13, p. 542,545

~%

文献:US2752368 , ; US2752337 , ; DE932799 , ;

~%

详细
文献:DE733297 , ; DRP/DRBP Org.Chem.

~%

详细
文献:US2172590 , ;

~%

详细
文献:Helvetica Chimica Acta, , vol. 32, p. 1764,1766

~%

详细
文献:US2296284 , ;

~%

文献:DE739083 , ; CH219649 , ; DRP/DRBP Org.Chem. US2310150 , ;

~%

文献:Chemische Berichte, , vol. 67, p. 1901,1904

~%

文献:US2461563 , ;

~%

文献:DE756002 , ; US2313732 , ;

~%

文献:US2153700 , ; DE672896 , ; Fortschr. Teerfarbenfabr. Verw. Industriezweige, vol. 24, p. 500

~%

文献:Helvetica Chimica Acta, , vol. 32, p. 1922,1930

~%

文献:Chemische Berichte, , vol. 69, p. 889,892

~%

文献:Chemische Berichte, , vol. 72, p. 1112,1116

~%

文献:DE765448 , ; DRP/DRBP Org.Chem.

~%

文献:US2229818 , ; CH215138 , ;

~%

文献:Chemische Berichte, , vol. 72, p. 1112,1116 DE717894 , ; DRP/DRBP Org.Chem.

~%

文献:US2259109 , ; FR844850 , ;

~%

详细
文献:US2152625 , ; DE697757 , ; DRP/DRBP Org.Chem. DE711823 , ;

~%

文献:DE722409 , ; DRP/DRBP Org.Chem.

~%

详细
文献:Tetrahedron, , vol. 7, p. 138,147

~%

文献:US2229599 , ;

~%

文献:US2265143 , ;

~%

文献:CH224834 , ;

~%

文献:DE739084 , ; DRP/DRBP Org.Chem.

~%

详细
文献:Helvetica Chimica Acta, , vol. 32, p. 1922,1930

~%

详细
文献:US2259109 , ; FR844850 , ;

~%

详细
文献:US2259109 , ; FR844850 , ;

~%

详细
文献:DE736847 , ;

~%

详细
文献:US2379832 , ;

~%

详细
文献:Recueil des Travaux Chimiques des Pays-Bas, , vol. 56, p. 137,143 Organic Syntheses, , vol. Coll. Vol. III, p. 207

~%

详细
文献:DE752829 , ; DRP/DRBP Org.Chem.
详细
文献:Helvetica Chimica Acta, , vol. 32, p. 1922,1930

~%

详细
文献:Helvetica Chimica Acta, , vol. 32, p. 1764,1766

 孕酮制备

由妊烯醇酮氧化得到。将干燥的甲苯加入干燥的反应锅内,加入环已酮及妊烯醇酮,搅拌溶解,蒸甲苯脱水至尽,迅速加入异丙醇铝,于115℃氧化反应2h,冷却至80℃左右,在搅拌下加入5%稀硫酸,静置分层,分去水层,甲苯层用水洗至中性后进行水蒸气蒸馏,蒸出甲苯及环已酮。冷却,过滤,滤渣用石油醚搅成浆状,过滤,以石油醚洗涤,干燥得黄体酮粗品。粗品溶于乙醇,用活性炭脱色,重结晶成品,收率80%。

 孕酮文献888

更多文献
H4 histamine receptors inhibit steroidogenesis and proliferation in Leydig cells.

J. Endocrinol. 223(3) , 241-53, (2014)

The histamine H4 receptor (HRH4), discovered only 13 years ago, is considered a promising drug target for allergy, inflammation, autoimmune disorders and cancer, as reflected by a steadily growing num...

Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression.

Breast Cancer Res. 17 , 26, (2015)

The emergence of hormone therapy resistance, despite continued expression of the estrogen receptor (ER), is a major challenge to curing breast cancer. Recent clinical studies suggest that epigenetic m...

Bioadhesive emulsions for control release of progesterone resistant to vaginal fluids clearance.

Int. J. Pharm. 477(1-2) , 495-505, (2014)

The aim of this study is to propose that mucoadhesive vaginal emulsions can be able to resist the clearance effect of vaginal fluid and to have an effective control release of progesterone. With this ...